AZD8421
AZD8421 is a small-molecule inhibitor from AstraZeneca, in registered phase 2 trials for ovarian cancer.
Overview
AZD8421 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by AstraZeneca, in ovarian cancer. Described in the registry record as a cdk2 inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a cdk2 inhibitor; the trial entries below carry the sponsor's wording.
1.AZD8421 slips into a pocket on its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"AZD8421" OR ABSTRACT:"AZD8421") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AZD8421, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentTILT-123
Shares Ovarian cancer and the tags pipeline, registry-only.
- TreatmentAdavosertib
Shares AstraZeneca and the tags pipeline, registry-only.
- TreatmentVistusertib
Shares AstraZeneca and the tags pipeline, registry-only.
- TreatmentUtomilumab
Shares Ovarian cancer and the tags pipeline, registry-only.
- TreatmentTHEO-260
Shares Ovarian cancer and the tags pipeline, registry-only.
- TreatmentPamiparib
Shares Ovarian cancer and the tags pipeline, registry-only.
- TreatmentCYH33
Shares Ovarian cancer and the tags pipeline, registry-only.
- TreatmentUpifitamab rilsodotin
Shares Ovarian cancer and the tags pipeline, registry-only.